Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Lido Advisors LLC

Lido Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 14,677 shares of the biopharmaceutical company’s stock after acquiring an additional 3,030 shares during the period. Lido Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $11,129,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in REGN. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $11,358,000. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Contravisory Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $6,327,000. Oxbow Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $3,342,000. Finally, Compass Financial Management LLC raised its position in shares of Regeneron Pharmaceuticals by 4,526.2% in the third quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after purchasing an additional 2,942 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $959.41 on Thursday. The company has a market cap of $99.25 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 1.21 and a beta of 0.10. The business has a 50 day moving average price of $811.95 and a 200 day moving average price of $745.49. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same period in the previous year, the business posted $11.83 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on REGN. Leerink Partners boosted their price objective on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the stock a “market perform” rating in a research note on Monday, November 2nd. Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a “market perform” rating in a research note on Monday, November 2nd. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Piper Sandler lifted their target price on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Finally, UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals News Summary

These are some of the REGN news items that stood out recently:

• Positive Sentiment: Regeneron collaborator Alnylam reported first-in-human results for CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved markers of liver injury, providing encouraging early evidence for a potential treatment opportunity. Article: Alnylam collaborator Regeneron advances CIDEBsiRNA with promising first-in-human results
• Positive Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru (garetosmab), Regeneron’s recently approved treatment for adults with the rare disorder fibrodysplasia ossificans progressiva. The partnership may support the drug’s distribution and patient access, although no sales impact was specified. Article: Soleo Health selected as a specialty pharmacy partner for Pasatru
• Neutral Sentiment: A Zacks article characterized REGN as a long-term value stock, but the summary provided no new company-specific developments or valuation details that would clearly explain near-term trading. Article: Why Regeneron is a top value stock for the long term

Insider Buying and Selling

In related news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $542,700. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock valued at $25,025,950 in the last ninety days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.